Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kensey Nash Evaluating Aegis Vortex Atherectomy System In Pilot Study

This article was originally published in The Gray Sheet

Executive Summary

Kensey Nash's recently initiated pilot study for its Aegis Vortex System (AVS) for treating occluded saphenous vein grafts is designed to support FDA approval for an estimated 300-patient pivotal trial.

You may also be interested in...



Kensey Nash

Secondary offering of 3.2 mil. shares of common stock at $9.50 each includes 2.7 mil. shares offered by the company and 500,000 offered by certain selling shareholders. A portion of the proceeds will be used to continue development of the Aegis Vortex atherectomy system to open coronary bypass grafts, conduct clinical trials and complete regulatory submissions for the device (1"The Gray Sheet" Aug. 16, 1999, p. 8). Funds also will be used for debt repayment and general corporate purposes. Prudential Vector Healthcare Group was lead manager of the offering; PaineWebber and UBS Warburg were co-managers

Kensey Nash

Secondary offering of 3.2 mil. shares of common stock at $9.50 each includes 2.7 mil. shares offered by the company and 500,000 offered by certain selling shareholders. A portion of the proceeds will be used to continue development of the Aegis Vortex atherectomy system to open coronary bypass grafts, conduct clinical trials and complete regulatory submissions for the device (1"The Gray Sheet" Aug. 16, 1999, p. 8). Funds also will be used for debt repayment and general corporate purposes. Prudential Vector Healthcare Group was lead manager of the offering; PaineWebber and UBS Warburg were co-managers

Kensey Nash

Proposed secondary offering of 3.2 mil. shares of common stock includes 2.5 mil. shares to be offered by the company and 700,000 shares to be offered by certain selling shareholders. A portion of the proceeds will be used to continue development of the Aegis Vortex atherectomy system to open coronary bypass grafts, conduct clinical trials and complete regulatory submissions for the device (1"The Gray Sheet" Aug. 16, 1999, p. 8). Funds will also be used for debt repayment and general corporate purposes. Prudential Vector Healthcare Group is lead manager of the offering; PaineWebber and Warburg Dillon Read will act as co-managers

Related Content

UsernamePublicRestriction

Register

MT012177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel